Thermo Fisher Scientific Inc Receives Mixed Financial Ratings

Thermo Fisher Scientific Inc suffers from weak growth indicators. Despite high ratings from the Growth Investor model, several key areas reveal significant weaknesses.

Date: 09-01-2025

AI Rating: 4

Overview of Financial Ratings
Thermo Fisher Scientific Inc (TMO) has received a mixed rating of 46% using the Growth Investor model. Although it achieves passing grades in P/E ratio, revenue growth in relation to EPS growth, and sales growth rate, it fails concerning key earnings metrics.

Earnings Per Share (EPS)
The report reveals multiple failings in EPS growth metrics. TMO has not maintained positive earnings growth in the current quarter, nor has it shown growth greater than prior quarters. In addition, the current quarter's EPS growth does not exceed its historical growth rate, indicating a decline in performance for this crucial metric.

Profit Margins
Although no specific profit margin metrics are cited, the failure in EPS growth suggests potential issues regarding profitability. Low profit margins could reflect on TMO's ability to generate income effectively.

Revenue Growth
Despite other weaknesses, the report indicates passing revenue growth metrics, which means that while the company is generating sales, this is not translating into sustained earnings growth.

Current Financial Health
TMO's total debt/equity ratio failure raises concerns about its leverage and financial stability. A high level of debt compared to equity can indicate greater risk, especially if profitability is not strong.

In conclusion, despite some passing metrics, the overall outlook for Thermo Fisher Scientific Inc may drive cautious investor sentiment given the glaring weaknesses in EPS growth, profit margins, and high debt levels. Investors should weigh these factors when considering potential impacts on stock prices.

Stocks: TMO